



News Release

Suven Revenue stands flat, R&D spent at 25% of Revenue Obtains 2 US, 3 European and 4 Indian Product Patents during the qtr

HYDERABAD, INDIA (Jan' 28, 2008) – SUVEN LIFE Science's Board of Directors meeting held today in Hyderabad announced the results that the revenues are at Rs. 8788 lacs for the nine months ending Dec' 2007 compared to Rs. 8585 lacs for the corresponding previous period. PAT stood at Rs. 632 lacs compared to Rs. 841 for the corresponding previous period, a decline of 25%.

The segmental revenue for the nine months from DDDSS increased by 93 % to Rs.1341 lacs from Rs.696 lacs. However, there is reduction in CRAMS revenue for the nine months from Rs. 7797 lacs to Rs. 7154 lacs, by 8%.

For the 3rd quarter ending Sep' 2007, the revenues stood at Rs.2898 lacs compared to the corresponding previous quarter of Rs.3225 lacs. The PAT stood at Rs.201 lacs compared to Rs.383 lacs for the corresponding previous quarter. The main factor which influenced the deficit in revenues and profits is the Rupee appreciation while comparing with previous year figures.

Suven's major thrust on innovative R&D in Drug Discovery continues with a total expenditure (revenue & capital) of Rs 2223 lacs recording about 25% of revenue for nine months.

During the Quarter Suven has been granted 2 Product patents from USA, 3 Product Patents from European Union and 4 From Indian Patent offices.

Suven will commence Phase I clinical trials with its IND candidate SUVN-502 in Switzerland during February, 2008.

Suven Life Sciences is a Hyderabad based Biopharmaceutical Company; a Collaborative Research Partner (CRP) since 2006 in Drug Discovery for global pharma major is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery Development Support Services (DDDSS) since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 300 professionals with the state of the art infrastructure for Drug Discovery and development activities and the front end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;